Privacy Statement

Your privacy is important to us. Aadi Bioscience, Inc. (“Aadi”) has established a comprehensive privacy program and designated a chief privacy officer, designed to help us respect and protect your privacy rights. This Privacy Statement will let you know what Personal Information (PI) Aadi may collect, how we use it, how we protect it, and your rights and choices with respect to your PI. This Privacy Statement applies to all Aadi operations as well as websites, mobile applications and digital services (“websites”) that link to or post it. It is incorporated into and made a part of our Terms of Use for this website, which include provisions that limit Aadi’s liability.

PI We Collect and How We Use It

Depending on your interactions with Aadi, we may collect the following PI:

  • Name/Alias/Signature;
  • Full Date of Birth;
  • Identifiable Photograph/Video/Physical Characteristics or Descriptions;
  • Gender;
  • Business/Professional Contact Information (e.g., title, company name, business address, business email address, business phone/fax number);
  • Personal Contact Information (e.g., personal address, personal email address, personal phone/fax, personal web/internet address, family member names);
  • Online identifiers that correspond to your device(s) (e.g., personal IP [Internet Protocol] address, cookies, RFID, etc.);
  • Employment/Professional Job or Qualifications Information;
  • Health Information;
  • Biographic Information;
  • Financial and Government Identifying Numbers (e.g., Social Security number);
  • Criminal/Conviction Records (e.g., on Federal Exclusion list);
  • Biometric Identifiers;
  • Website Utilization and Social Media Use;
  • Education Information;
  • Commercial Information, (e.g. purchasing, consuming history or tendencies);
  • Inferences Reflecting Preferences

We collect PI from a number of sources, including:

  • Employees, potential employees and their family members;
  • Patients and clinical/medical trial participants;
  • Clinical/medical investigators and staff conducting clinical/medical research;
  • Health care professionals;
  • Adverse event reporters and subjects;
  • Consumers;
  • Customers;
  • Investors and shareholders;
  • Vendors, suppliers and contractors;
  • Business partners;
  • Government officials

We process/use PI for the following business or commercial purposes:

  • Activities for public health and interest;
  • Activities as an employer to support and fulfill our obligations to our employees;
  • Research and development of our products;
  • Compliance with legal or regulatory obligations (e.g., adverse event reporting, exercising or defending legal claims, financial disclosure reporting);
  • Business and market research;
  • Market research for our products and services;
  • Study recruitment;
  • Marketing and sales of our products;
  • Communicating information about our products, responding to requests and registration for services;
  • Providing patient assistance;
  • Finance and tax activities;
  • Statistical analytics;
  • Event management;
  • Contracting and business planning activities; and
  • Administration of other legal and business processes that are in Aadi’s legitimate interest, inclusive of company record retention, safeguarding our physical and electronic workplace, and website management.

Aadi may share your PI with

  • Aadi employees and affiliates;
  • Health care professionals;
  • Vendors, suppliers and contractors;
  • Business partners; and
  • Government officials (e.g., law enforcement authorities, the courts, regulatory authorities).

Where permitted by law, Aadi may also enhance or merge information, including PI, with information obtained from third parties for the same purposes shared above. PI may also be used for profiling for the same purposes shared above. You may object to profiling via automated-decision making by contacting us using the information in the “How to Contact Us” section below.

You do not have to share your PI with us, but if you choose not to share your PI, we may not be able to provide you with certain information, products or services.

In the ordinary course of business, Aadi sometimes collects Social Security numbers to fulfill legal or regulatory obligations or for other administrative purposes. We respect the confidentiality of Social Security numbers and we avoid the unnecessary collection of them, limit access to them, and disclose them only (i) according to Aadi’s internal privacy policy and procedures, (ii) with those third parties who are legally or contractually obligated to protect them, and (iii) as required or permitted by law.

Through this website, Aadi may:

  • Collect your Name and Personal Contact Information if you opt in to receive communications (such as requests for information, responses to inquiries, newsletters, etc.). Aadi may also use this information to verify your relationship with Aadi and take other actions in order to respond to your request.
  • Collect online identifiers that correspond to your device(s) that do not directly identify you in order to improve, manage and secure our websites, network systems and other assets; verify your relationship with us; understand your interests and preferences; and take other actions that may be necessary to respond to your request.
  • Analyze your website usage including the date and time of your website session, geographic location, how you have navigated the website, and other information collected through our web beacons, cookies, third-party and digital advertising, Google Analytics®; and social media plug-ins. This information is collected for our legitimate business purposes.

Web beacons: A web beacon (also known as an “action tag” or “clear GIF technology”) is a tiny graphic on a web page or in an email message designed to track pages viewed or messages opened, and allows the collection of web log information. Web log information is gathered by the computer that hosts our website (called a “web server”) when you visit one of our websites. We may use web beacons to help determine which email messages sent by us were opened and whether a message was acted upon. Web beacons also help Aadi analyze the effectiveness of websites by measuring the number of visitors to a site or how many visitors clicked on key elements of a site.

Cookies: A cookie is a small data file that a website can place on your computer’s hard drive where your internet browser files are kept. A cookie saves you the trouble of reentering certain information in some registration areas because cookies can be used to enable a site to “remember” information a visitor has previously inputted. A cookie also helps deliver content and features likely to be of interest to you, based on your previous activities on our site, and to track how sections of the website are used. Cookies can be placed on your computer both by us and by third parties with whom we have a relationship, such as web analytic services and advertising network services. In addition, cookies may be used to remarket employment opportunities to you in the United States. With most internet browsers or other software, you can change your browser settings to erase cookies from your computer hard drive, block all cookies or receive a warning before a cookie is stored. Please check your browser instructions to learn more about these functions. If you reject cookies, functionality of the site may be limited, and you may not be able to take advantage of many of the site’s features.

  • Choices about Cookies: If you would like to opt out of, or manage, cookies used for targeted advertising, you may do so by following the options provided by the Network Advertising Initiative and the Digital Advertising Alliance. Ads displayed to you using this technology will usually have an AdChoices logo in the corner, which you can also click on to begin the same opt-out process. Additionally, if you receive ads on a social media site, you can check that site’s privacy statement and terms of use to determine how to stop seeing such ads.
  • Do Not Track: There are different ways you can prevent tracking of your online activity. One of them is setting a preference in your browser that alerts websites you visit that you do not want them to collect certain information about you. This is referred to as a Do Not Track (“DNT”) signal. Please note that currently our websites and web-based resources do not respond to these signals from web browsers. At this time, there is no universally accepted standard for what a company should do when a DNT signal is detected.

Third-Party and Digital Advertising: We may partner with third-party advertising networks to manage our advertising on other sites. Our ad network partners may place cookies and web beacons and similar digital markers on your browser when you visit our websites to collect information about your activities over time on this and third-party websites, apps and other online services, to provide you targeted advertising based upon your interests. We may also share PI about you with third parties in order to have those third parties, on our behalf, directly serve advertising to you on their websites.

Google Analytics: Google Analytics may be used to help make our website work better and to help us understand what parts of the website are being utilized. Google Analytics uses technical tools, such as first-party cookies and JavaScript® code, to collect information about visitors. The Google Analytics service tracks visitors to the site who have JavaScript enabled. Google Analytics anonymously tracks how visitors interact with a website, including where they came from and what they did on a site. Google Analytics collects the information set forth above from users. This information is used to administer and update the website, and we will assess whether the visitors to the site match the expected site demographics and determine how key audiences are navigating the content. First-party cookies (such as the Google Analytics cookie) and third-party cookies (such as the DoubleClick cookie) will be used to report how your ad impressions, other uses of ad services, and interactions with these ad impressions and ad services are related to visits to this site.

  • Opt-Out Provision: Google Analytics offers an opt-out provision for website visitors who do not want their data to be collected. You can receive more information about this option here.
  • Google’s Use of Data: Google and its wholly owned subsidiaries may retain and use, subject to the terms of its Privacy Policy (located here, or at another such URL that Google may provide from time to time), information collected in your use of the Google Analytics Information Disclosures and Sharing.

Social Media Plug-ins: Our websites may use social media plug-ins to enable you to share information with others easily. When you visit our websites, the operator of the social media plug-in that is on our website can place a cookie on your computer that lets that operator recognize individuals on their website who have previously visited our sites. Social media plug-ins may allow social media websites to receive directly identifiable information about you that shows you have visited our website. The social media plug-in may collect this information for visitors, whether or not they specifically interact with the plug-in on our website. Social media plug-ins also allow the social media website to share information about your activities on our website with other users of their social media website. Aadi does not control any of the content from social media plug-ins. For more information about social plug-ins from social media websites, you should refer to those sites’ privacy and data-sharing statements.

Children’s Information

This website is not intended for or designed for individuals under the age of 18. We do not knowingly collect PI from any person under the age of 18, unless a parent or guardian provides consent.

Reasons We Share PI

We may share your PI with third parties in connection with work that they do for or with Aadi, for purposes consistent with those listed above. These third parties must agree to protect the PI and to use it only as directed by Aadi.

We may also be required to disclose your information in response to lawful information requests for PI by law enforcement authorities, the courts or regulatory authorities, including complying with national security or law enforcement requests.

In the event that Aadi may decide to reorganize or divest part or all of its business, including its information databases, through a sale, divestiture, merger, acquisition or other means of transfer, then PI may be shared with, sold, transferred, rented, licensed or otherwise provided or made available by Aadi to third parties in connection with the contemplated transaction (without your consent or any further notice to you). In such circumstances, Aadi will seek written assurances that the PI will be protected appropriately.

Where We Transfer and Work With PI

This website is owned and operated by Aadi in the United States. However, any information collected on this website may be transferred to other Aadi affiliates and third parties worldwide. These affiliates and third parties may in turn transmit PI to other Aadi affiliates and third parties. Some of Aadi’s affiliates and third parties may be located in countries that do not require the same level of data protection as the country you reside in. When transferring PI across country borders, Aadi and its affiliates utilize appropriate transfer mechanisms as applicable (which may include consent, Standard Contractual Clauses, existing adequacy decisions, etc.). Nevertheless, all of Aadi’s affiliates are required to treat PI in a manner consistent with this notice, and Aadi’s internal global privacy policies. By using this website, you consent to the collection, storage, and processing of your PI in the United States and in any country to which we may transfer your information in the course of our business operations.

How Long We Keep PI

PI will be saved for a period of time needed to fulfill legitimate and lawful business purposes in accordance with our record retention policies and applicable laws and regulations.

How We Secure PI

We provide reasonable physical, technical and procedural safeguards to protect PI we work with and maintain. We limit access to PI to authorized employees and third parties who need access to carry out their assigned roles and responsibilities on behalf of Aadi. Although we strive to protect the PI we work with and maintain, no security system can prevent all potential security breaches.

Your Rights and Choices

Upon verification of your identity and as applicable by law, you have the right to request information from us on how your PI is being used and with whom it is being shared. You also have the right and choice to request to see and receive a copy of the PI that we have about you, request that we correct, restrict the processing of, and/or erase/delete your PI.

In limited circumstances, you may have the right to have your information transmitted to another entity or person in a machine-readable format.

There may be exceptions that apply to your request.

To exercise your rights, you or your authorized representative may submit a request to info@aadibio.com or by contacting us using one of the methods listed in the Contact Us section of our website.

You will not be discriminated against for exercising any of your rights.

California Privacy Rights

California Civil Code Section 1798.83 entitles California residents who have an established business relationship with Aadi the right to request information regarding Aadi’s disclosure of certain PI to third parties for their direct marketing purposes. To make a request for such information, you may contact us using the information in the “How to Contact Us” section below.

California Consumer Privacy Act (CCPA) entitles California residents to certain rights with regard to their PI. Those rights have been incorporated into this Privacy Statement.

We do not sell personal information.

How to Contact Us

You may make any of the above requests by using the contact information below:

Aadi Bioscience, Inc.

1-888-BIO-AADI

info@aadibio.com

You may also contact us at the above if you have questions about this Privacy Statement.

How to Submit a Complaint

If you wish to raise a complaint on how we have handled your PI, you can contact our privacy officer at privacy@aadibio.com, who will investigate the matter.

If you are not satisfied with our response or believe we are not processing your PI in accordance with the law, you can register a complaint with a relevant regulatory authority.

Links to Third-Party Websites

As a convenience to our visitors, this website may contain links to other sites owned and operated by third parties that we believe may offer useful information. The policies and procedures we describe here do not apply to those sites. We are not responsible for the collection or use of PI at any third-party sites. Therefore, we disclaim any liability for any third party’s use of PI obtained through using the third-party website. We suggest contacting those sites directly for information on their privacy, security, data collection and distribution policies.

Changes to Our Privacy Practices

We may update this Privacy Statement from time to time. When we do update it, for your convenience, we will make the updated statement available on this page. We will always handle your PI in accordance with the Privacy Statement in effect at the time it was collected unless we provide you with the new notice and/or obtain your consent, as appropriate.

Last Updated: November, 2021

Indication

FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound) is a prescription medicine used to treat locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors in adult patients.

Important Safety Information Indication

How is FYARRO taken?
FYARRO is administered by intravenous infusion into your vein over 30 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.

Who should not receive FYARRO?

Do not use FYARRO if you have had a severe allergic reaction to sirolimus or human albumin. You should tell your health care provider before receiving FYARRO if you are allergic to sirolimus (Rapamune®), everolimus (Afinitor®), temsirolimus (Torisel®) or Human Albumin.

What are the possible side effects of FYARRO?

FYARRO can cause serious side effects, including the following:

Mouth ulcers and sores

Mouth ulcers and sores are common during treatment with FYARRO and can be severe. When you start treatment with FYARRO, your health care provider may also prescribe an alcohol-free mouthwash to reduce the likelihood of getting mouth ulcers or sores and to reduce their severity. Follow your health care provider’s instructions on how to use this prescription mouthwash. If you develop pain, discomfort, or open sores in your mouth, tell your health care provider. Your health care provider may tell you to restart this mouthwash or to use a special mouthwash or mouth gel that does not contain alcohol, peroxide, iodine, or thyme.

Decreased blood cell counts

FYARRO can cause you to have decreased red blood cells, platelets, and white blood cells. Your health care provider should do blood tests to check your blood cell counts before you start and during treatment with FYARRO.

Infections

Infections such as pneumonia, or a bacterial, fungal, or viral infection may develop while on treatment with FYARRO. Viral infections may include active hepatitis B in people who have had hepatitis B in the past (reactivation). In some people (including adults and children), these infections may be severe and can lead to death. If infections occur, urgent treatment may be required. Tell your health care provider right away if you have a temperature of 100.5°F or above, have chills, or do not feel well. Symptoms of hepatitis B or infection may include the following: fever, chills, skin rash, joint pain and swelling, tiredness, loss of appetite, nausea, pale stools or dark urine, yellowing of the skin, or pain in the upper right side of the stomach.

Low potassium

FYARRO can cause your blood potassium levels to fall. Low blood potassium levels can make you feel weak and can affect your heart rhythm if severe. Your health care provider should do blood tests to check your potassium levels before you start and during treatment with FYARRO.

Increased blood sugar and fat (cholesterol and triglyceride) levels in blood

Your health care provider should do blood tests to check your fasting blood sugar, cholesterol, and triglyceride levels in the blood before you start and during treatment with FYARRO. Diabetic patients should monitor their fasting serum glucose more frequently.

Lung inflammation

FYARRO can cause inflammation of the lung. If you develop a persistent cough, chest pain, or shortness of breath, let your doctor know right away.

Bleeding

FYARRO can cause serious and sometimes fatal bleeding. If you develop bleeding, let your doctor know right away.

Severe allergic reactions

Call your health care provider or get medical help right away if you get signs and symptoms of a severe allergic reaction including rash, itching, hives, difficulty breathing or swallowing, flushing, chest pain, or dizziness.

Harm to an unborn child

FYARRO can cause harm to your unborn baby. For women who are able to become pregnant, your health care provider will give you a pregnancy test before you start treatment with FYARRO. You should use effective birth control during treatment and for 12 weeks after your last dose of FYARRO. Men with a female partner should use effective birth control during treatment and for 12 weeks after your last dose of FYARRO.

Infertility

FYARRO may affect fertility in woman and men and may affect your ability to become pregnant if you are female, or your ability to father a child if you are male. Talk to your health care provider if this is a concern for you.

Breastfeeding

Do not breastfeed during treatment and for 2 weeks after your last dose.

Vaccinations

You should not receive a live vaccine or be around people who have recently received a live vaccine during your treatment with FYARRO. If you are not sure about the type of vaccine, ask your health care provider.

Human albumin

Human serum albumin (HSA), an ingredient in FYARRO, is made from human blood. The blood donors for HSA are checked for infections and the HSA is processed to get rid of germs in the product. Because of these steps, HSA carries only an extremely small risk for transmission of viral diseases and “mad cow” disease, also called variant Creutzfeldt-Jakob disease (vCJD). No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin.

The most common side effects with FYARRO include the following:

  • Mouth ulcers or sores
  • Feeling weak or tired
  • Rash
  • Infection
  • Nausea
  • Swelling of arms, hands, feet, ankles, face, or other parts of the body
  • Diarrhea
  • Body pain
  • Decreased weight
  • Decreased appetite
  • Cough
  • Vomiting
  • Altered taste

Other possible side effects that may occur with FYARRO:

  • Absence of menstrual periods (menstruation). You may miss 1 or more menstrual period. Tell your health care provider if this happens

What should I tell my health care provider before taking FYARRO?

Before taking FYARRO, tell your health care provider about all your medical conditions, including if you:

• Have or have had kidney problems
• Have or have had liver problems
• Have diabetes or high blood sugar
• Have high blood cholesterol levels
• Have any infections
• Previously had hepatitis B

Tell your health care provider about all of the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Using FYARRO with certain other medicines can cause serious side effects. Keep a list of medicines you take and show it to your health care provider when you get a new medicine. Especially tell your health care provider if you take the following:

• St John’s wort (Hypericum perforatum)
• Medicine for:
  — Fungal infections
  — Bacterial infections
  — Tuberculosis
  — Seizures
  — HIV-AIDS
  — Heart conditions or high blood pressure

  • Medicines that weaken the immune system (your body’s ability to fight infections and other diseases)

Ask your health care provider or pharmacist if you are not sure if your medicine is one of those taken for the conditions listed above. If you are taking any medicines for the conditions listed above, your health care provider might need to prescribe a different medicine or your dose of FYARRO may need to be changed. Tell your health care provider before you start taking any new medicine.

What should I do if I receive FYARRO from my health care provider?

You should not drink grapefruit juice or eat grapefruit during your treatment with FYARRO. It may make the amount of FYARRO in your blood increase to a harmful level.

Tell your health care provider if you have any side effect that bothers you or does not go away.

These are not all the possible side effects of FYARRO. For more information, ask your health care provider or pharmacist. Call your doctor for medical advice about side effects.

The risk information provided here is not comprehensive. To learn more, talk about FYARRO with your health care provider or pharmacist. The FDA-approved product labeling can be found at www.FYARRO.com or 1-888-BIO-AADI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information.

Indication

FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound) is a prescription medicine used to treat locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors in adult patients.

Indication
Important Safety Information

How is FYARRO taken?
FYARRO is administered by intravenous infusion into your vein over 30 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.

Who should not receive FYARRO?

Do not use FYARRO if you have had a severe allergic reaction to sirolimus or human albumin. You should tell your health care provider before receiving FYARRO if you are allergic to sirolimus (Rapamune®), everolimus (Afinitor®), temsirolimus (Torisel®) or Human Albumin.

What are the possible side effects of FYARRO?

FYARRO can cause serious side effects, including the following:

Mouth ulcers and sores

Mouth ulcers and sores are common during treatment with FYARRO and can be severe. When you start treatment with FYARRO, your health care provider may also prescribe an alcohol-free mouthwash to reduce the likelihood of getting mouth ulcers or sores and to reduce their severity. Follow your health care provider’s instructions on how to use this prescription mouthwash. If you develop pain, discomfort, or open sores in your mouth, tell your health care provider. Your health care provider may tell you to restart this mouthwash or to use a special mouthwash or mouth gel that does not contain alcohol, peroxide, iodine, or thyme.

Decreased blood cell counts

FYARRO can cause you to have decreased red blood cells, platelets, and white blood cells. Your health care provider should do blood tests to check your blood cell counts before you start and during treatment with FYARRO.

Infections

Infections such as pneumonia, or a bacterial, fungal, or viral infection may develop while on treatment with FYARRO. Viral infections may include active hepatitis B in people who have had hepatitis B in the past (reactivation). In some people (including adults and children), these infections may be severe and can lead to death. If infections occur, urgent treatment may be required. Tell your health care provider right away if you have a temperature of 100.5°F or above, have chills, or do not feel well. Symptoms of hepatitis B or infection may include the following: fever, chills, skin rash, joint pain and swelling, tiredness, loss of appetite, nausea, pale stools or dark urine, yellowing of the skin, or pain in the upper right side of the stomach.

Low potassium

FYARRO can cause your blood potassium levels to fall. Low blood potassium levels can make you feel weak and can affect your heart rhythm if severe. Your health care provider should do blood tests to check your potassium levels before you start and during treatment with FYARRO.

Increased blood sugar and fat (cholesterol and triglyceride) levels in blood

Your health care provider should do blood tests to check your fasting blood sugar, cholesterol, and triglyceride levels in the blood before you start and during treatment with FYARRO. Diabetic patients should monitor their fasting serum glucose more frequently.

Lung inflammation

FYARRO can cause inflammation of the lung. If you develop a persistent cough, chest pain, or shortness of breath, let your doctor know right away.

Bleeding

FYARRO can cause serious and sometimes fatal bleeding. If you develop bleeding, let your doctor know right away.

Severe allergic reactions

Call your health care provider or get medical help right away if you get signs and symptoms of a severe allergic reaction including rash, itching, hives, difficulty breathing or swallowing, flushing, chest pain, or dizziness.

Harm to an unborn child

FYARRO can cause harm to your unborn baby. For women who are able to become pregnant, your health care provider will give you a pregnancy test before you start treatment with FYARRO. You should use effective birth control during treatment and for 12 weeks after your last dose of FYARRO. Men with a female partner should use effective birth control during treatment and for 12 weeks after your last dose of FYARRO.

Infertility

FYARRO may affect fertility in woman and men and may affect your ability to become pregnant if you are female, or your ability to father a child if you are male. Talk to your health care provider if this is a concern for you.

Breastfeeding

Do not breastfeed during treatment and for 2 weeks after your last dose.

Vaccinations

You should not receive a live vaccine or be around people who have recently received a live vaccine during your treatment with FYARRO. If you are not sure about the type of vaccine, ask your health care provider.

Human albumin

Human serum albumin (HSA), an ingredient in FYARRO, is made from human blood. The blood donors for HSA are checked for infections and the HSA is processed to get rid of germs in the product. Because of these steps, HSA carries only an extremely small risk for transmission of viral diseases and “mad cow” disease, also called variant Creutzfeldt-Jakob disease (vCJD). No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin.

The most common side effects with FYARRO include the following:

  • Mouth ulcers or sores
  • Feeling weak or tired
  • Rash
  • Infection
  • Nausea
  • Swelling of arms, hands, feet, ankles, face, or other parts of the body
  • Diarrhea
  • Body pain
  • Decreased weight
  • Decreased appetite
  • Cough
  • Vomiting
  • Altered taste

Other possible side effects that may occur with FYARRO:

  • Absence of menstrual periods (menstruation). You may miss 1 or more menstrual period. Tell your health care provider if this happens

What should I tell my health care provider before taking FYARRO?

Before taking FYARRO, tell your health care provider about all your medical conditions, including if you:

  • Have or have had kidney problems
  • Have or have had liver problems
  • Have diabetes or high blood sugar
  • Have high blood cholesterol levels
  • Have any infections
  • Previously had hepatitis B

Tell your health care provider about all of the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Using FYARRO with certain other medicines can cause serious side effects. Keep a list of medicines you take and show it to your health care provider when you get a new medicine. Especially tell your health care provider if you take the following:

  • St John’s wort (Hypericum perforatum)
  • Medicine for:
      — Fungal infections
      — Bacterial infections
      — Tuberculosis
      — Seizures
      — HIV-AIDS
      — Heart conditions or high blood pressure
  • Medicines that weaken the immune system (your body’s ability to fight infections and other diseases)

Ask your health care provider or pharmacist if you are not sure if your medicine is one of those taken for the conditions listed above. If you are taking any medicines for the conditions listed above, your health care provider might need to prescribe a different medicine or your dose of FYARRO may need to be changed. Tell your health care provider before you start taking any new medicine.

What should I do if I receive FYARRO from my health care provider?

You should not drink grapefruit juice or eat grapefruit during your treatment with FYARRO. It may make the amount of FYARRO in your blood increase to a harmful level.

Tell your health care provider if you have any side effect that bothers you or does not go away.

These are not all the possible side effects of FYARRO. For more information, ask your health care provider or pharmacist. Call your doctor for medical advice about side effects.

The risk information provided here is not comprehensive. To learn more, talk about FYARRO with your health care provider or pharmacist. The FDA-approved product labeling can be found at www.FYARRO.com or 1-888-BIO-AADI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information.

Indication

FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound) is a prescription medicine used to treat locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors in adult patients.